Search Clinical Trials | Froedtert & the Medical College of Wisconsin

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

179 results

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROC]

To compare the non-inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo-oophorectomy (BSO) to reduce the risk of ovarian cancer among women with deleterious BRCA1 germline mutations.

Protocol No

NRG-CC008

Sub Category

Gynecologic Cancers

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies

Screening Protocol for Tumor Antigen Expression Profiling and HLA typing for Eligibility

Protocol No

ADP-0000-001-SCR

Sub Category

Gynecologic Cancers

Prostate and Urologic Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Head and Neck Cancers

Gastrointestinal Cancers

Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Protocol No

ALLIANCE-N0577-CODEL

Sub Category

Brain and Spine Cancers

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)

Belantamab mafodotin vs pom/dex in RRMM

Protocol No

GSK-207495-DREAMM-03

Sub Category

Hematologic/Blood Related Cancers

A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer.

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.

Protocol No

SWOG-S1602

Sub Category

Prostate and Urologic Cancers

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects with Relapsed or Refractory Multiple Myeloma

A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

Protocol No

TENEOBIO-TNB-383B

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in CML Patients with Molecular Evidence of Disease

Ruxolitinib Phosphate and Dasatinib or Nilotinib in Treating Patients With Chronic Myeloid Leukemia

Protocol No

SWOG-S1712-CML

Sub Category

Hematologic/Blood Related Cancers

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5%.

Protocol No

NRG-CC003

Sub Category

Brain and Spine Cancers

Thoracic Cancers

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for NSNSCLC

Protocol No

NRG-LU003

Sub Category

Thoracic Cancers

A Phase II Trial of Nab-Paclitaxel plus Cisplatin plus Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

The purpose of this study is to find out if the study drugs nab-paclitaxel, cisplatin, and
gemcitabine given together are safe and effective.

Protocol No

HRI-AX-CL-PANC-PI-13301

Sub Category

Gastrointestinal Cancers

Randomized Phase II/III Study Of Venetoclax (Abt 199) Plus Chemoimmunotherapy For Myc/Bcl2 Double-Hit And Double Expressing Lymphomas

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Protocol No

ALLIANCE-A051701-DLBCL

Sub Category

Hematologic/Blood Related Cancers

Phase I-II Study Evaluating the Dosing, Safety, Efficacy and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) Administered in Combination with Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed with Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

The objective is to evaluate safety and compare progression free survival between subjects receiving neoadjuvant chemotherapy (NACT) plus GEN-1 versus NACT alone

Protocol No

CELSION-201-17-201

Sub Category

Gynecologic Cancers

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Protocol No

ADCT-301-201-HL

Sub Category

Hematologic/Blood Related Cancers

Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Predict Non-Relapse
Mortality after Allogeneic Transplantation in Older Adults

Composite Health Assessment Risk Model (CHARM) for Older Adults

Protocol No

CTN-1704

Sub Category

Hematologic/Blood Related Cancers

A Phase 2 Study of Lisocabragene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients with Agressive B-Cell NHL (017006)

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (Transcend-Pilot-017006)

Protocol No

JUNO-JCAR017-017006

Sub Category

Hematologic/Blood Related Cancers

Phase II Randomized Trial Of Neo-Adjuvant Chemotherapy Followed By Surgery And Post-Operative Radiation Versus Surgery And Post-Operative Radiation For Organ Preservation Of T3 And T4a Nasal And Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Testing the Addition of Chemotherapy to the Treatment of Cancer of the Sinonasal Area

Protocol No

ECOG-EA3163

Sub Category

Head and Neck Cancers

Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Protocol No

NRG-BN003

Sub Category

Brain and Spine Cancers

A Phase II Study of the Efficacy and Pharmacogenomics of Salvage Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML)

Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia

Protocol No

IIT-ATALLAH-CLAGM-AML

Sub Category

Hematologic/Blood Related Cancers

Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

The purpose of this study is to determine the safety and tolerability of gilteritinib given in combination with atezolizumab in participants with relapsed or treatment refractory FMS-like tyrosine kinase 3 (FLT3) mutated AML and to determine the composite complete remission (CRc) rate for participants who either discontinued the study or completed 2 cycles of gilteritinib given in combination with atezolizumab.

Protocol No

ASTELLAS-2215-CL-1101

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

A Phase 1 Study to Evaluate The Effect Of Hepatic Impairment On The Pharmacokinetics And Safety Of Lorlatinib In Advanced Cancer Patients

This is a phase 1 study in advanced cancer patients with varied hepatic fucntions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.

Protocol No

PFIZER-B7461009

Sub Category

Hematologic/Blood Related Cancers

Early Phase/Multiple Disease Site Cancers

Thoracic Cancers

Sarcoma

Skin Cancers

Prostate and Urologic Cancers

Head and Neck Cancers

Gynecologic Cancers

Gastrointestinal Cancers

Endocrine Cancers

Breast Cancers